JACKSONVILLE, Florida, November 6, 2018 / PRNewswire / – As reported by Johnson & Johnson Vision, Dr. Noel A. Brennan, head of the myopia control project at Johnson & Johnson Vision, is authoritative A researcher and specialist in this field will present data on the progression of myopia and talk about experimental methods of its control at the annual Conference of the American Academy of Optometry 2018, which will be held November 7-10, 2018 in San Antonio, Texas, USA.
Myopia, or myopia, is an impairment of vision in which objects located far away look blurry and fuzzy. This disorder is the most common cause of visual impairment and is closely related to the increasing incidence of other eye diseases, such as cataracts, glaucoma, retinal dystrophy and, as a result, possible loss of vision. In the absence of adequate diagnosis and treatment, complications of myopia can become the leading cause of irreversible vision loss and blindness over the next few decades, and by 2050 the incidence of such diseases can double.
“Despite the increase in the incidence of a geometric progression, a very small number of methods used to control the progression of myopia have proven to be effective. Moreover, the pathological community receives much less attention from the scientific community than other eye diseases,” said Dr. Brennan. Given the lack of a globally approved methodology for controlling myopia, specialists in the field of ophthalmology around the world, making decisions about the need for therapy in one form or another, rely mainly on their own experience and opinions to the estimated often lacking evidentiary basis to develop more informed and thoughtful patient’s treatment plan. “
The conference will present the results of two meta-analyzes:
In a paper titled Evidence Based Evidence-Based Methods of Myopia, Dr. Brennan assesses the effectiveness of existing methods of treating myopia, including 0.01% atropine instillation, orthokeratology, multi-zone soft contact lenses, glasses (E-line, DIMS), prolonged finding in the open air, based on an analysis of 32 published studies.
The analysis carried out by this specialist shows that the most visible therapeutic result today is an increase in the length of the axis of the eye by 0.43 mm and a refraction of 1.05D. This result is not achieved in every patient and can lead to a “rebound” effect. In a world based on medical reporting data, these results represent the best scenario for the progression of the disease, as well as being the basis for teaching practitioners and patients basic principles of treatment and control of myopia. The analysis of Dr. Brennan also showed that instillations of atropine in a concentration of 0.01% do not have clinical efficacy in terms of controlling the increase in the length of the axis of the eye.
Doctor Brennan delivers a poster presentation on this topic on Friday, November 9, 2018, from 10:00 to 12:00 in the exhibition hall of the Henry B. Gonzalez Convention Center.
The study entitled “The effect of age and race on increasing the length of the axis of the eye in myopic children” is the first meta-analysis of the axial lengthening of the eyes in children with myopia. These data were obtained on the basis of the analysis of 63 studies in the field of progression of myopia in childhood. Dr. Brennan developed new formulas that take into account the axial length of the patient’s eye instead of using the refractive progression. The parameters of the axial length of the eye can be measured many times without cycloplegia – paralysis of the ciliary muscle, which does not allow the lens to focus on objects that are near.
Against the backdrop of increasing actions for effective control of myopia, the axial length of the eye is potentially capable of becoming a more common indicator of disease progression that helps practicing an ophthalmic disease.
Sourced from TASS.ru and machine translated for your benefit